Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 53.14% is in line with its 5-year average of 50.91%, around the middle of its 5-year range (0.00%–100.00%).
34.80% below its 12-month average of 81.50%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
53.14%
GROSS MARGIN AVG TTM
81.50%
GROSS MARGIN AVG 3Y
58.96%
GROSS MARGIN AVG 5Y
50.91%
GROSS MARGIN AVG 10Y
40.20%
GROSS MARGIN AVG 15Y
37.68%
GROSS MARGIN AVG 20Y
34.23%
CURRENT VS TTM AVG
-34.80%
CURRENT VS 3Y AVG
-9.87%
CURRENT VS 5Y AVG
+4.38%
CURRENT VS 10Y AVG
+32.18%
CURRENT VS 15Y AVG
+41.05%
CURRENT VS 20Y AVG
+55.24%
SECTOR MEDIAN · HEALTHCARE
42.90%
median of 617 covered companies
CURRENT VS SECTOR MEDIAN
+23.87%
vs the sector median at left
CAMP4 Therapeutics Corporation
Market Cap
$242.85M
Gross Margin
53.14%
TTM Avg
81.50%
3Y Avg
58.96%
5Y Avg
50.91%
Market Cap
$243.81M
Gross Margin
N/A
TTM Avg
31.32%
3Y Avg
30.59%
5Y Avg
32.68%
Market Cap
$243.95M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$238.61M
Gross Margin
-24677.94%
TTM Avg
-13289.35%
3Y Avg
-6830.59%
5Y Avg
-4553.73%
Market Cap
$235.77M
Gross Margin
79.48%
TTM Avg
71.93%
3Y Avg
74.52%
5Y Avg
72.98%
Market Cap
$235.77M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$250.48M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CAMP4 Therapeutics Corporation (CAMP) | $242.85M | 53.14% | 81.50% | 58.96% | 50.91% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | 31.32% | 30.59% | 32.68% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.95M | 0.00% | 0.00% | 0.00% | 0.00% |
| Invivyd, Inc. (IVVD)vs › | $243.08M | 91.35% | 93.31% | 46.66% | 31.10% |
| InflaRx N.V. (IFRX)vs › | $238.61M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
| High Tide Inc. (HITI)vs › | $236.81M | 25.85% | 26.57% | 27.09% | 30.11% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.77M | 79.48% | 71.93% | 74.52% | 72.98% |
| Galectin Therapeutics Inc. (GALT)vs › | $235.77M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $250.48M | 0.00% | 0.00% | 25.00% | 50.00% |
| BioAge Labs Inc. (BIOA)vs › | $232.73M | 99.39% | 50.00% | 25.00% | 25.00% |
Gross Margin
53.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 59.81% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 47.67% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-08-31 | 100.00% |
| 2023-05-31 | 38.17% |
| 2023-02-28 | 35.33% |
| 2022-11-30 | 33.74% |
| 2022-08-31 | 39.84% |
| 2022-05-31 | 39.62% |
| 2022-02-28 | 41.02% |
| 2021-11-30 | 40.74% |
| 2021-08-31 | 42.23% |
| 2021-05-31 | 40.72% |
| 2021-02-28 | 42.22% |
| 2020-11-30 | 39.77% |
| 2020-08-31 | 36.88% |
| 2020-05-31 | 38.71% |
| 2020-02-29 | 38.23% |
| 2019-11-30 | 38.18% |
| 2019-08-31 | 40.40% |
| 2019-05-31 | 39.76% |
| 2019-02-28 | 39.67% |
| 2018-11-30 | 41.11% |
| 2018-08-31 | 41.46% |
| 2018-05-31 | 40.14% |
| 2018-02-28 | 40.70% |
| 2017-11-30 | 40.77% |
| 2017-08-31 | 41.04% |
| 2017-05-31 | 42.51% |
| 2017-02-28 | 41.55% |
| 2016-11-30 | 42.13% |
| 2016-08-31 | 41.57% |
| 2016-05-31 | 38.22% |
| 2016-02-29 | 38.92% |
| 2015-11-30 | 35.59% |
| 2015-08-31 | 36.25% |
| 2015-05-31 | 35.96% |
| 2015-02-28 | 35.53% |
| 2014-11-30 | 34.96% |
| 2014-08-31 | 34.62% |
| 2014-05-31 | 34.28% |
| 2014-02-28 | 34.45% |
| 2013-11-30 | 33.06% |
| 2013-08-31 | 33.74% |
| 2013-05-31 | 34.39% |
| 2013-02-28 | 31.10% |
| 2012-11-30 | 31.65% |
| 2012-08-31 | 32.13% |
| 2012-05-31 | 31.18% |
| 2012-02-28 | 28.16% |
| 2011-11-26 | 31.05% |
| 2011-08-27 | 34.98% |
| 2011-05-28 | 27.30% |
| 2011-02-28 | 28.91% |
| 2010-11-27 | 26.05% |
| 2010-08-28 | 24.98% |
| 2010-05-29 | 23.24% |
| 2010-02-28 | 20.25% |
| 2009-11-28 | 19.21% |
| 2009-08-29 | 20.07% |
| 2009-05-30 | 20.47% |
| 2009-02-28 | 63.71% |
| 2008-11-29 | 29.58% |
| 2008-08-30 | 32.04% |
| 2008-05-31 | 33.79% |
| 2008-03-01 | 25.31% |
| 2007-12-01 | 31.28% |
| 2007-09-01 | 19.33% |
| 2007-06-02 | -9.93% |
| 2007-03-03 | 20.63% |
| 2006-11-30 | 20.79% |
| 2006-08-31 | 24.18% |
| 2006-05-31 | 23.59% |
| 2006-02-28 | 25.46% |
| 2005-11-30 | 25.54% |
| 2005-08-31 | 23.27% |
| 2005-05-31 | 22.48% |
| 2005-02-28 | 18.55% |
| 2004-11-30 | 18.05% |
| 2004-08-31 | 20.31% |
| 2004-05-31 | 18.45% |
| 2004-02-28 | 15.45% |
| 2003-11-30 | 15.22% |
| 2003-08-31 | 13.22% |
| 2003-05-31 | 7.03% |
| 2003-03-01 | 15.17% |
| 2002-11-30 | 18.27% |
| 2002-08-31 | 23.09% |
